[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"thoracic-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:thoracic-cancer":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,18,0,[8,44,80,116,137,165,186,214,240,272,300,327,351,385,407,433,457,484],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100053816","lucinae-registry-thoracic-cancers-during-pregnancy-100053816",false,"NCT07699861","LUCINAE Registry: Thoracic Cancers During Pregnancy","LUCINAE: LUng and Thoracic Cancers In pregNAncy rEgistry","LUCINAE","Inclusion Criteria:\n\n* 1\\. All patients with a diagnosis of thoracic cancer (including lung cancer, mesothelioma, thymic epithelial tumors, neuroendocrine tumors or sarcoma of the thorax and other rare thoracic entities) and pregnancy (positive pregnancy test) including:\n\n  1. Patients receiving a diagnosis of thoracic cancer during pregnancy\n  2. Patients who became pregnant while having active thoracic cancer\n  3. Patients previously treated for a thoracic cancer and becoming pregnant in the 5 years following end of treatment OR Men with a diagnosis of thoracic cancer (including lung cancer, mesothelioma, thymic epithelial tumors, neuroendocrine tumors or sarcoma of the thorax and other rare thoracic entities), who were undergoing active oncological treatment at the time their partner conceived their child.\n* 2\\. Available information about pregnancy outcomes\n* 3\\. Age ≥ 18 years\n\nExclusion Criteria:\n\n* 1\\. Patient missing data about thoracic cancer stage and diagnosis\n* 2\\. For retrospective patients, documented refusal to the use of clinical data for research purposes","ALL","18 Years",{"count":20,"type":21},100,"ESTIMATED","OBSERVATIONAL","The LUCINAE Registry is an international, multicenter observational study collecting data on patients with thoracic cancers (including lung cancer) who are expecting a child. This includes women diagnosed during pregnancy, women who become pregnant during or after cancer, and men receiving cancer treatment at the time their partner conceives.\n\nBecause thoracic cancers during pregnancy are rare, there is limited information to guide clinical decisions. This registry aims to describe patient characteristics, diagnostic approaches, treatments, and maternal and fetal outcomes. Data are collected retrospectively and prospectively from participating centers.\n\nThe results of this registry are expected to improve understanding of thoracic cancers in this setting and support the development of future clinical recommendations.",[25,26,27],"Lung Cancer","Thoracic Cancer","Cancer During Pregnancy",[29,30],"thoracic cancers during pregnancy","Lung cancer during pregnancy","RECRUITING","2026-07-07",{"date":34,"type":35},"2026-07-13","ACTUAL",{"date":37,"type":21},"2026-06",{"date":39,"type":21},"2035-12",{"name":41,"class":42},"Oncology Institute of Southern Switzerland","OTHER",4,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":54,"briefSummary":57,"conditions":58,"keywords":62,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":79},"100624280","phase-1-ph-iii-sodium-thiosulfate-for-otoprotection-during-cisplatin-stop-cis-100624280","NCT07407582","Ph. I\u002FII Sodium Thiosulfate for OtoProtection During Cisplatin (STOP-CIS)","Phase I\u002FII Open Label Trial of Intravenous Sodium Thiosulfate (Pedmark®) as Otoprotectant in Adults Receiving Cisplatin Chemotherapy (STOP-CIS)","Inclusion Criteria:\n\n* Participants have provided informed consent prior to initiation of any study-specific activities.\n* At least 18 years of age, male or female, at the time of signing the informed consent.\n* ECOG Performance Status 0-1\n* Histologically or cytologically confirmed treatment-naïve cancer.\n* Scheduled to receive an FDA-approved, on-label indication, standard of care systemic cisplatin-based regimen (at least 200 mg\u002Fm2 cumulative dose) for any untreated any solid malignancy deemed by the treating physician\n\nExclusion Criteria:\n\n* Prior cisplatin exposure due to a cancer treatment history\n* Concurrent ototoxic medication unable to be safely discontinued or switched to a non-toxic alternative\n* Planned radiation to the head or neck prior to, during, or within 3 months of completion of cisplatin\n* History of severe hypersensitivity to sulfite, sodium thiosulfate, or any components\n* Baseline serum sodium \\> 145 mmol\u002FL or any grade ≥ 3 electrolyte abnormality\n* Cisplatin infusion duration greater than 6 hours\n* Females during pregnancy or breastfeeding, and childbearing potential, unwilling to use a method of contraception during treatment\n* Male subjects with a pregnant partner who are unwilling to practice abstinence or use a condom during treatment\n* Subject likely not to be available to complete all protocol-required study visits or procedures, and\u002For to comply with all required study procedures (i.e., Clinical Outcome Assessments) to the best of the subject's and investigator's knowledge.\n* History or evidence of any other clinically significant disorder, condition, or disease (with the exception of those outlined above) that, in the opinion of the investigator, if consulted, would pose a risk to subject safety or interfere with the study evaluation, procedures, or completion.",{"count":52,"type":21},25,"INTERVENTIONAL",[55,56],"PHASE1","PHASE2","The purpose of this study is to assess the safety and effectiveness of a drug called Pedmark® sodium thiosulfate (STS) in reducing hearing impairment with standard of care cisplatin therapy. The safety and effectiveness of STS in reducing hearing loss has been well established in children and is approved for use in the pediatric and young adult population. However, information in adult patients is limited. As most cisplatin is administered in the adult population, this investigation would be of benefit.",[59,60,61,26],"Solid Tumor Malignancies","Testicular Cancer","Head and Neck Cancer",[63,64,65,66,67,68,69],"Cisplatin","Otoprotectant","Cancer","Hearing Impairment","Sodium Thiosulfate","Adults","Solid Tumor","2026-06-16",{"date":72,"type":35},"2026-06-18",{"date":74,"type":35},"2026-05-18",{"date":76,"type":21},"2028-04-30",{"name":78,"class":42},"University of Arizona",1,{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":53,"phases":89,"briefSummary":90,"conditions":91,"keywords":98,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":5},"100586992","phase-1-study-to-evaluate-the-safety-tolerability--efficacy-of-tng462-in-combination-in-pdac--nsclc-patients-100586992","NCT06922591","Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients","A Phase 1\u002F2, Multicenter, Open-Label Study to Evaluate Safety, Tolerability & Antitumor Activity of TNG462 in Combination With Other Agents in Patients With Pancreatic Cancer With MTAP Loss and Pancreatic or Non-Small Cell Lung Cancer With MTAP Loss & RAS Mutation","Inclusion Criteria:\n\n1. Is ≥18 years of age at the time of signature of the main study ICF.\n2. Has an ECOG PS of 0 or 1.\n3. Has a tumor with loss of MTAP protein or bi-allelic deletion of the MTAP gene\n4. Arms A and B only: Has a tumor with a RAS mutation\n5. Pathologically documented metastatic PDAC or locally advanced, recurrent or metastatic NSCLC\n6. Has received prior standard therapy\n7. Arms A and B only: Must not have received prior RAS-targeted therapy\n8. Has evidence of measurable disease based on RECIST v1.1.\n9. Adequate organ function\n10. Must be able to swallow tablets.\n11. Negative pregnancy test at screening\n12. Written informed consent must be obtained according to local guidelines\n\nExclusion Criteria:\n\n1. Has received prior treatment with a PRMT5 inhibitor, or MAT2A inhibitor\n2. Arms A and B only: Prior enrollment in any phase 3 clinical trial of RMC-6236 or RMC-9805\n3. Known allergy, hypersensitivity or intolerance to TNG462 (all arms), RMC-6236 Arm A), RMC-9805 (Arm B), mFOLFIRINOX (Arm C), gemcitabine\u002Fnab-paclitaxel (Arm D) or their excipients\n4. Has uncontrolled intercurrent illness that will limit compliance with the study requirements.\n5. Has an active infection requiring systemic therapy.\n6. Is currently participating in or has planned concurrent participation in a study of another investigational agent or device.\n7. Has impairment of GI function or disease that may significantly alter the absorption of the oral medications\n8. Has known or suspected active or untreated CNS metastases associated with progressive neurological symptoms\n9. Has current active liver disease from any cause\n10. Is known to be HIV positive, unless all the following criteria are met:\n\n    1. CD4+ count ≥300\u002FµL.\n    2. Undetectable viral load.\n    3. Receiving highly active antiretroviral therapy\n11. Has clinically relevant cardiovascular disease\n12. History of or presence of active interstitial lung disease\n13. Is a female patient who is pregnant or lactating\n14. Is unwilling or unable to comply with the scheduled visits, study treatment administration plan, laboratory tests or other study procedures and study restrictions.\n15. Has a prior or ongoing clinically significant illness, medical condition, surgical history, physical finding, or laboratory abnormality that, in the investigator's opinion may affect the safety of the patient or impair the ability to assess study results",{"count":88,"type":21},183,[55,56],"TNG462-C102 is a Phase 1\u002F2, open-label, multicenter study designed to determine the safety, tolerability, PK, PD, and preliminary antineoplastic activity of oral TNG462 in combination with RMC-6236, RMC-9805, mFOLFIRINOX or gemcitabine\u002Fnab-paclitaxel. The study comprises a dose escalation phase and a dose expansion phase.",[92,93,94,95,96,25,97,26],"PDAC","PDAC - Pancreatic Ductal Adenocarcinoma","NSCLC","RAS Mutation","MTAP Deletion","Pancreatic Cancer Metastatic",[99,100,101,102,103,104,105],"PRMT5 inhibitor","RAS G12D","Multi RAS","RMC-9805","RMC-6236","Thoracic","Targeted therapy","2026-05-12",{"date":108,"type":35},"2026-05-14",{"date":110,"type":35},"2025-05-31",{"date":112,"type":21},"2027-12",{"name":114,"class":115},"Tango Therapeutics, Inc.","INDUSTRY",{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":120,"acronym":121,"eligibilityCriteria":122,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":123,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":125,"conditions":126,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":79},"100594175","variability-and-post-op-aes-does-preoperative-cardiopulmonary-variability-assessment-identify-risk-of-postoperative-adverse-events-following-thoracic-surgery-100594175","NCT07016022","Variability and Post-op AEs: Does Preoperative CardioPulmonary Variability Assessment Identify Risk of Postoperative Adverse Events Following Thoracic Surgery","CPVA","Inclusion Criteria:\n\n* Adult patient (≥18 years of age)\n* Patients undergoing major thoracic resection for lung, esophageal or gastric cancer or mediastinal tumour (at least lobectomy, pneumonectomy, esophagectomy, gastrectomy, or mediastinal tumour resection)\n\nExclusion Criteria:\n\n* Urgent\u002Femergent cases\n* Patients with pre-existing atrial fibrillation or arrhythmia (persistent\u002Fparoxysmal)\n* Patients that are pacemaker dependent\n* Patients unable to participate in preoperative testing protocol (CardioPulmonary Variability Assessment)\n* Patients that are pregnant",{"count":124,"type":21},130,"Major thoracic surgery is high risk as it carries a significant risk of postoperative Adverse Events (AEs), where patients experience complications and do not recover as expected. These AEs can increase the risk of mortality, hospital length of stay, as well as healthcare costs. The investigators' aim is to improve surgical safety by pioneering a marked advance in preoperative prediction of postoperative AEs that will enable individualized targeted perioperative pathways to prevent postoperative AEs. Given that illness and stress are associated with a loss in physiologic variability (e.g. heart and respiration rate), the investigators will use heart and lung variability assessments to improve prediction of postoperative AEs. Therefore, this study aims to assess the feasibility of implementing a preoperative CardioPulmonary variability assessment; determine if preoperative CardioPulmonary variability is associated with postoperative AEs; and determine if this variability assessment is superior and complementary to existing measures of risk and frailty.",[26,127],"Complication,Postoperative","2026-04-27",{"date":130,"type":35},"2026-05-01",{"date":132,"type":35},"2025-07-01",{"date":134,"type":21},"2026-07-01",{"name":136,"class":42},"Ottawa Hospital Research Institute",{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":4,"eligibilityCriteria":143,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":144,"targetDuration":4,"studyType":53,"phases":146,"briefSummary":148,"conditions":149,"keywords":154,"overallStatus":157,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":162,"leadSponsor":163,"locationsCount":79},"100622892","early-phase-1-immune-checkpoint-inhibitor-ici-drug-drug-interaction-ddi-study-100622892","NCT07389525","Immune Checkpoint Inhibitor (ICI)-Drug-Drug Interaction (DDI) Study","Assessment of Drug-Drug Interactions Between Immune Checkpoint Inhibitors and Cytochrome P450 Substrates: Immune Checkpoint Inhibitor (ICI)-Drug-Drug Interaction (DDI) Study","Inclusion Criteria:\n\n* ≥ 18 years old at the time of informed consent\n* Diagnosed with cancer AND initiating therapy with single agent or combination therapy that includes an immune checkpoint inhibitor (e.g., atezolizumab, cemiplimab, durvalumab, ipilimumab, nivolumab, pembrolizumab, relatlimab, tremelimumab)\n* Ability to provide written informed consent and HIPAA authorization\n\nExclusion Criteria:\n\n* Actively pregnant or breastfeeding\n* Body weight less than 50 kg or a BMI \\>35\n* Low baseline hemoglobin, defined as \\\u003C10 g\u002FdL\n\n  * Note: if a prospective patient's hemoglobin returns to the normal range, they can be re-screened for trial inclusion)\n* Past medical history of chronic liver disease, signs and symptom of liver disease (e.g., jaundice, ascites), or aspartate aminotransferase \\>96 U\u002FL, alanine aminotransferase \\> 80 IU\u002FL, alkaline phosphatase \\>260 U\u002FL, or total bilirubin \\> 2.6 mg\u002FdL\n\n  * Note: if a prospective patient's liver function tests return to the normal ranges, they can be re-screened for trial inclusion)\n* Past medical history of chronic kidney disease, signs and symptom of kidney disease (e.g., decreased urine output, swelling in feet and ankles), or estimated glomerular filtration rate \\\u003C45 mL\u002Fminute\u002F1.73 m2 BSA\n\n  * Note: if a prospective patient's kidney function returns to the normal range, they can be re-screened for trial inclusion)\n* Poor performance status that makes it unlikely the patient will complete 3 cycles of immune checkpoint inhibitor (at the treating oncologist's discretion)\n* Diagnosis or past medical history of autoimmune disorder, including systemic lupus erythematosus, Crohn's disease, Sjogren's syndrome, multiple sclerosis, type 1 diabetes mellitus, Behcet's disease, and ankylosing spondylitis\n* History of intolerance, allergic reaction, or hypersensitivity to any of the study drugs (tizanidine, bupropion, flurbiprofen, omeprazole, dextromethorphan, midazolam, rosuvastatin)\n* Current infection requiring medical treatment (note: if a prospective patient's infection resolves, they can be re-screened for trial inclusion)\n* Concomitant treatment with systemic immunosuppressant drugs (see Appendix 3 for list)\n\n  * Note: patients may be re-screened for trial eligibility if they discontinue any exclusionary drugs for ≥7 days prior to Study Visit 1\n* Concomitant treatment with a CYP\u002Ftransporter probe cocktail drug or strong inhibitors, inducers, or agents that affect the pharmacokinetics of the relevant CYP enzymes or drug transporters (see Appendix 4 for list)\n\n  * Note: patients may be re-screened for trial eligibility if they discontinue any exclusionary drugs for ≥7 days prior to Study Visit 1\n* Are unwilling\u002Funable to avoid drugs of abuse, tobacco products or marijuana, or consuming more than 2 alcoholic drinks per day during the study\n* Inability to take oral medication",{"count":145,"type":21},80,[147],"EARLY_PHASE1","Immune checkpoint inhibitors (ICIs) (also called \"immunotherapy\") are an effective family of anti-cancer drugs, but they can cause serious side effects. Some evidence suggests these side effects might happen because ICIs interact with other drugs that you may already be taking, making those drugs work differently, or causing more side effects. The purpose of this study is to see whether ICIs impact how the liver processes other drugs. To do this, participants will be given a probe cocktail of 7 different FDA-approved drugs that are processed in different ways in the liver.",[150,151,26,152,153],"Gastrointestinal Neoplasms","Genitourinary Cancer","Sarcoma","Melanoma",[155,156],"cytokines","immune checkpoint inhibitor","NOT_YET_RECRUITING","2026-04-21",{"date":160,"type":35},"2026-04-24",{"date":37,"type":21},{"date":112,"type":21},{"name":164,"class":42},"Indiana University",{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":171,"eligibilityCriteria":172,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":173,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":175,"conditions":176,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":79},"100542393","patient-generated-health-data-collection-during-chemoradiotherapy-for-lung-cancer-100542393","NCT06342284","Patient-Generated Health Data Collection During Chemoradiotherapy for Lung Cancer","Patient-Generated Health Data Collection During Chemoradiotherapy for Lung Cancer: A Pilot Study","PGHD","Inclusion Criteria:\n\n* Plan for fractionated (≥15 treatments) proton beam thoracic radiotherapy with curative intent for lung cancer\n* Non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC) histology is permitted.\n* Concurrent chemotherapy is permitted but not required..\n* Previous thoracic radiotherapy is allowed.\n* Ability to complete study surveys in English or Spanish\n* Age \\>\u002F= 18\n* Concurrent enrollment on other trials is permitted\n* Patients who already use wearable devices and\u002For smartphones that monitor physical activity are eligible for this trial, provided they agree to utilize the devices provided by the study team during the study period\n* All patients must sign study-specific informed consent prior to study entry\n\nExclusion Criteria:\n\n* Ongoing treatment for another cancer that is expected to affect the toxicity profile of thoracic radiotherapy\n* Pregnancy or women of childbearing potential and men who are sexually active and not willing\u002Fable to use medically acceptable forms of contraception; this exclusion is necessary because the treatment involved in this study may be significantly teratogenic",{"count":174,"type":21},40,"This is an observational study involving the collection of patient-generated health data using an Apple Watch, a home pulse oximeter, and a smartphone during a course of proton beam radiotherapy for lung cancer. The study period over which this information is collected will range from the day of study enrollment until two weeks after radiotherapy completion. Subjects will complete a short satisfaction survey at the end of the study period. Other information that is collected as part of routine care for this patient population will be extracted from subjects' medical records during the study period and afterwards.",[26],"2026-04-06",{"date":179,"type":35},"2026-04-13",{"date":181,"type":35},"2024-03-22",{"date":183,"type":21},"2031-03-21",{"name":185,"class":42},"The New York Proton Center",{"id":187,"slug":188,"hasResults":11,"nctId":189,"briefTitle":190,"officialTitle":190,"acronym":191,"eligibilityCriteria":192,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":193,"targetDuration":4,"studyType":53,"phases":195,"briefSummary":197,"conditions":198,"keywords":204,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":208,"startDateStruct":209,"completionDateStruct":211,"leadSponsor":213,"locationsCount":79},"100463322","prospective-evaluation-of-pencil-beam-scanning-proton-therapy-for-previously-irradiated-tumors-100463322","NCT05313191","Prospective Evaluation of Pencil Beam Scanning Proton Therapy for Previously Irradiated Tumors","ReRT","Inclusion Criteria:\n\n* Age 18 years\n* Patient provides study specific informed consent prior to study entry.\n* Documented history and physical exam within 90 days prior to registration.\n* ECOG PS 0, 1, or 2 within 90 days prior to registration\n\nExclusion Criteria:\n\n* Non malignant systemic disease that would preclude the patient from receiving study treatment or would prevent required follow up.\n* Prior invasive non study malignancy unless disease free for ≥ 3 years\n\n  * Non melanoma skin cancer, low risk prostate cancer, well differentiated thyroid cancers, in situ carcinomas of the oral cavity, cervix, and other organs, and tumors that are not thought to impact the life expectancy of the patient are permissible.\n* History of active connective tissue disorder (i.e., systemic lupus erythematosus, scleroderma), dermatomyositis, xeroderma pigmentosum",{"count":194,"type":21},1800,[196],"NA","The goal of this clinical research trial is to study the use of differing investigational doses and scheduling for Proton Therapy for tumors previously treated with radiation therapy. Generally, when patients are first treated for cancer with radiation therapy, they are treated with traditional photon (or x-ray) radiation therapy, which uses high-energy waves to kill tumor cells. In some cases, the cancer either returns or a new tumor can present in a different part of the body. With the usual radiation treatment, the photon beams travel all the way through the body. As a result, healthy tissues in front of and behind the tumor are exposed to radiation. Physicians who treat these cases where the tumor has returned often use a much lower dose of radiation to prevent patients from experiencing serious and long-term side-effects. This dose is often not strong enough to destroy the cancerous tumor. Alternatively, they may also treat a smaller area than would be indicated for complete tumor eradication, again in an attempt to prevent serious and long-term toxicities, but at the cost of optimally treating the cancer. Proton therapy, however, may offer a chance to safely deliver a more effective dose and volume of radiation as it is more targeted and can spare healthy tissues surrounding the tumor.\n\nThe reason we are conducting this research study is to look at whether Proton therapy can be a better way to treat reoccurring tumors in patients who have previously received radiation therapy to the same area, compared to treatment approaches used to date.",[199,61,200,201,202,26,203],"CNS Cancer","GI Cancer","Gynecologic Cancer","Prostate Cancer","Breast Cancer",[205,65,206,207],"Reirradiation","Proton Therapy","Radiation Therapy",{"date":179,"type":35},{"date":210,"type":35},"2022-01-24",{"date":212,"type":21},"2028-01",{"name":185,"class":42},{"id":215,"slug":216,"hasResults":11,"nctId":217,"briefTitle":218,"officialTitle":219,"acronym":4,"eligibilityCriteria":220,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":221,"enrollmentInfo":222,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":224,"conditions":225,"keywords":226,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":232,"startDateStruct":234,"completionDateStruct":236,"leadSponsor":238,"locationsCount":79},"100567508","thoracic-surgery-by-the-medtronic-hugo-robotic-system-100567508","NCT06669104","Thoracic Surgery by the Medtronic Hugo™ Robotic System","Thoracic Surgery by the Medtronic Hugo™ Robotic System: A Prospective Single Centre Study","Inclusion Criteria:\n\n1. Age between 18 - 80 years\n2. Body mass index \\\u003C35 kg\u002Fm2\n3. Suitable for minimally invasive surgery\n4. Willingness to participate as demonstrated by giving informed consent\n\nExclusion Criteria:\n\n1. Contraindication to general anaesthesia\n2. Severe concomitant illness that drastically shortens life expectancy or increases risk of therapeutic intervention\n3. Untreated active infection\n4. Non-correctable coagulopathy\n5. Emergency surgery\n6. Vulnerable population (e.g. mentally disabled, pregnancy)","80 Years",{"count":223,"type":21},50,"The introduction of robot-assisted surgery is one of the biggest breakthroughs in surgery, and represents the most significant advancement in minimally invasive surgery of recent decades. One of the first surgical uses of the robot was in orthopaedics, neurosurgery and cardiac surgery. However, it's use has now been well recognized in thoracic surgical procedures ranging from mediastinal tumour resection to complex major lung resections.\n\nRobotic surgery by the da Vinci Surgical System (Intuitive Surgical, Inc) has been one of the most commonly used robotic systems in surgery. The robotic system overcomes the limitations of the standard thoracoscopic approach and allows for precise dissection in a confined space. These advantages include stable operator-controlled camera, high- definition 3D magnified view of 10 to 12 times, articulating instruments with seven degrees of freedom, motion scaling, and tremor filtration.\n\nRecently the Medtronic Hugo™ surgical robotic system has passed the CE mark. This robotic platform, made up of modular surgical arms on wheeled carts, has started its operation in human in Latin America, Europe and the Asia-Pacific region. The Hugo™ system is designed to provide a lower barrier to entry for hospitals looking to expand their reach in robotic surgery. Compared to the platform by Intuitive Surgical, Hugo™can be customized with up to four independent arms, and rolled to different locations in a hospital when needed.\n\nThe investigator's centre is the first robotic surgical centre in Hong Kong since 2005. Over the years, the investigator have established the centre to be one of the leading centre in Hong Kong and the region, with involvement in various new development in thoracic robotic procedures, publications and books, and more recently in robotic endo-lumenal procedures.\n\nIn this study, the investigator evaluate the early surgical outcome and objective functional outcome of patients undergoing robotic thoracic surgery by the Medtronic Hugo™ surgical robotic system.",[26],[227,228,229,230],"robotic assisted thoracic surgery","minimally invasive surgery","lung cancer","mediastinal tumour","2026-03-18",{"date":233,"type":35},"2026-03-20",{"date":235,"type":35},"2025-05-01",{"date":237,"type":21},"2027-08-31",{"name":239,"class":42},"Chinese University of Hong Kong",{"id":241,"slug":242,"hasResults":11,"nctId":243,"briefTitle":244,"officialTitle":245,"acronym":246,"eligibilityCriteria":247,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":248,"targetDuration":250,"studyType":22,"phases":4,"briefSummary":251,"conditions":252,"keywords":259,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":263,"startDateStruct":265,"completionDateStruct":267,"leadSponsor":269,"locationsCount":271},"100592655","prospective-data-collection-initiative-on-thoracic-malignancies-100592655","NCT06996249","Prospective Data Collection Initiative on Thoracic Malignancies","Prospective Data Collection Initiative on Thoracic Malignancies - a Prospective Observational Cohort Study","DuTOC","Inclusion Criteria:\n\n* Age ≥ 18 years;\n* Histo\u002Fcytopathological proof of a thoracic malignancy, or a strong suspicion (after imaging and multidisciplinary board);\n* Informed consent for longitudinal observational data collection;\n\nExclusion Criteria:\n\n* Mentally challenged patients that are unable to provide conscientious informed consent as determined by the investigator.\n* Inability to provide a written or electronic informed consent.",{"count":249,"type":21},12000,"50 Years","Survival after cancer diagnosis strongly depends on local tumor extent, lymph node involvement and the presence of distant metastases. However, there remains great inter-patient variability regarding treatment outcome. A combination of molecular factors, biochemical factors, histopathological features, genomic profile, environmental factors and other clinical factors are likely to influence prognosis and treatment effect, independent from tumor stage. It is however still unclear which, how, and to what extent these factors will influence tumor recurrence and mortality in both early stage (I-III) and late stage (IV) thoracic malignancies such as lung cancer.\n\nAlthough the results from prospective clinical trials will remain the backbone of evidence-based medicine, this concerns a highly selected patient population since the large majority (85%-95%) of patients with cancer do not participate in clinical trials for various reasons. It is unlikely that trial participation will significantly improve in the near future. This fact has the following implications:\n\n1. It is highly desirable to validate the results from clinical trials in the general patient population. This is complicated by the fact that the documentation of patients treated in general practice (i.e. outside the scope of clinical trials) is largely insufficient to provide comparable patient cohorts in terms of prognostic characteristics and treatment parameters.\n2. There is an ever increasing number of therapeutic interventions available for which its efficacy depends on known and unknown tumor-specific, clinical, demographic and other patient characteristics. Large numbers of patients are required to test the relevance of these variables.\n3. As a result of rapid technical and drug developments, new minimally invasive treatment options such as stereotactic irradiation or ablation techniques or sublobar resections and new targeted and immunotherapeutic treatments have entered the clinic. These interventions have potentially less side effects compared to the conventional treatments. Still, these new interventions will have to prove their effectiveness, safety and superiority (or non-inferiority) in a real world setting.\n4. Many hypotheses related to further optimization of personalized medicine can currently not be tested as they require a large prospective cohort of patients, and a less time-consuming and costly research infrastructure.\n\nA prospective observational cohort study has the potential to fill the gap between prospective randomized trials (efficacy) and patients treated in general practice (effectiveness) and it will enable accrual of clinical trials (innovation).",[25,26,253,254,255,256,257,258],"Lung Cancer, Nonsmall Cell","Adenocarcinoma","Squamous Cell Carcinoma","Large Cell Lung Cancer","Thymus Cancer","Mesothelioma",[260,261],"Dutch lung cancer cohort","lung cancer cohort","2026-03-02",{"date":264,"type":35},"2026-03-03",{"date":266,"type":35},"2025-08-15",{"date":268,"type":21},"2030-01-01",{"name":270,"class":42},"Dutch Society of Physicians for Pulmonology and Tuberculosis",10,{"id":273,"slug":274,"hasResults":11,"nctId":275,"briefTitle":276,"officialTitle":277,"acronym":278,"eligibilityCriteria":279,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":280,"targetDuration":282,"studyType":22,"phases":4,"briefSummary":283,"conditions":284,"keywords":288,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":292,"startDateStruct":294,"completionDateStruct":296,"leadSponsor":298,"locationsCount":79},"100589104","curatively-intended-thoracic-reirradiation-100589104","NCT06950073","Curatively Intended Thoracic Reirradiation","CUratively Intended Thoracic REirradiation: An Observational Study of High-dose Reirradiation of Thoracic Tumours: A Multicentre Prospective Registration Protocol","CureLung","Inclusion Criteria:\n\n* Radiotherapy of thoracic lesion(s) (loco-regional lung cancer recurrence, new primary lung cancer, or solitary oligo metastasis) with the aim of long-term local control.\n* Reirradiation type 1 or type 2, i.e. previous radiotherapy to the thorax as per ESTRO-EORTC consensus definition of reirradiation \\[Andratschke 2022\\]. For the sake of this study, multiple treatments to the lungs will be classified as type 2 reirradiation.\n* Verification of malignancy based on biopsy. If no biopsy is available, the decision of reirradiation should be agreed upon in a multidisciplinary conference.\n* Available digital dose plan(s) from former radiotherapy course(s) (DICOM files) - note that multiple re-treatments are allowed.\n* Adequate lung function to tolerate treatment, at the discretion of the treating physician.\n* Ability to complete a radiotherapy course with the aim of local control.\n* ECOG Performance status 0-2.\n* Estimated life expectancy ≥ 6 months\n* Age ≥18 years\n* Signed informed consent\n\nExclusion Criteria:\n\n* Uncontrolled other malignancy.\n* The primary and the reirradiation treatment may not be quasi-simultaneous (i.e. the two treatments should be planned independently)\n* Pregnancy\n* Radiotherapy to a minimum CTV mean dose of 45 Gy for SCLC and 50 Gy for NSCLC and oligometastatic lesions. Treatment schedule according to local protocols and treating physician preference.",{"count":281,"type":21},500,"10 Years","The number of long-term lung cancer (LC) survivors increases, however many patients are diagnosed with recurrent or new thoracic cancers. High-dose reirradiation (reRT) is promising but associated with high severe toxicity rates. Existing studies are small lacking high-quality data, with no clear correlation between toxicity risk and delivered radiotherapy (RT) dose.\n\nThis Danish multicentre prospective cohort study aims to provide a framework for collecting radiotherapy-related toxicity data, loco-regional control, and overall survival data for patients with thoracic cancer undergoing reirradiation; with the ultimate aim of providing safe reirradiation to more patients.\n\nAs a secondary aim, guidelines for dose accumulation and provisional constraints for the organs at risk will be used to establish a uniform treatment strategy for reirradiation.\n\nThe CURE Lung trial will provide high-impact, globally missing data. This project will ensure full utilization of and learning from the trial, adding SDM, PROMs, and modality referral to the trial. It will model the correlation between toxicity burden and doses, enabling individualized reRT with optimized dose prescription based on toxicity risk and patient preferences, and assisting in the decision-making on the prescription dose and optimal modality. This will ensure safe reRT for the increasing number of long-term LC survivors.",[285,286,287,25,26],"Radiotherapy Side Effect","Radiation Toxicity","Oncology",[205,289,290,291,25,287,286],"Aarhus","Denmark","Thoracic cancer",{"date":293,"type":35},"2026-03-04",{"date":295,"type":35},"2025-10-10",{"date":297,"type":21},"2035-05-01",{"name":299,"class":42},"University of Aarhus",{"id":301,"slug":302,"hasResults":11,"nctId":303,"briefTitle":304,"officialTitle":305,"acronym":4,"eligibilityCriteria":306,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":307,"enrollmentInfo":308,"targetDuration":4,"studyType":53,"phases":310,"briefSummary":312,"conditions":313,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":318,"lastUpdatePostDateStruct":319,"startDateStruct":321,"completionDateStruct":323,"leadSponsor":325,"locationsCount":79},"100479346","phase-4-erector-spinae-block-for-thoracic-surgery-100479346","NCT05521789","Erector Spinae Block for Thoracic Surgery","Erector Spinae Blocks for Thoracic Surgery","Inclusion Criteria:\n\n* pulmonary resection\n* 18\\\u003Cage\\\u003C90\n\nExclusion Criteria:\n\n* pleurodesis\n* decortication\n* emergent surgery\n* local anesthetic allergy\n* intraoperative complication (inadvertent hemorrhage or conversion to open surgery)\n* bilateral pulmonary resection","90 Years",{"count":309,"type":21},70,[311],"PHASE4","The aim of this study is to determine if erector spinae injections with bolus infusions with local anesthetic decrease postsurgical pain and opioid consumption in patients undergoing pulmonary resection surgery.",[314,315,316,26,317],"Pulmonary Neoplasm","Pulmonary Cancer","Thoracic Diseases","Thoracic Neoplasms","2026-02-23",{"date":320,"type":35},"2026-02-25",{"date":322,"type":35},"2022-07-22",{"date":324,"type":21},"2027-07-21",{"name":326,"class":42},"George Washington University",{"id":328,"slug":329,"hasResults":11,"nctId":330,"briefTitle":331,"officialTitle":331,"acronym":4,"eligibilityCriteria":332,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":333,"targetDuration":4,"studyType":53,"phases":335,"briefSummary":336,"conditions":337,"keywords":340,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":341,"lastUpdatePostDateStruct":342,"startDateStruct":344,"completionDateStruct":346,"leadSponsor":348,"locationsCount":350},"100468120","surge-supporting-underrepresented-minorities-in-genomics-based-cancer-trial-enrollment-intervention-100468120","NCT05375643","SURGE: Supporting UnderRepresented Minorities in Genomics-based Cancer Trial Enrollment (Intervention)","Inclusion Criteria:\n\n* Adult (age 18 years or older)\n* Black, Latinx, OR older adult (age 70 years or older)\n* Scheduled for a new patient consultation\n* Suspected or confirmed advanced malignancy (requiring active treatment)\n* Gastrointestinal, hematologic, or thoracic cancer\n* DFCI patient at Longwood\u002FChestnut Hill, DFCI satellite at St. Elizabeth's Medical Center, or DFCI satellite at Merrimack Valley\n\nExclusion Criteria:\n\n* Malignancy or former malignancy that requires only surveillance\n* Not continuing care at a participating DFCI site\n* Speaks a language other than English or Spanish\n* Unable to provide consent",{"count":334,"type":21},210,[196],"SURGE aims to increase equity in clinical trial enrollment by addressing barriers to genomic testing, which is increasingly needed to assess precision clinical trial eligibility and access standard precision therapies. The study is an interventional pilot meant primarily to assess the feasibility of the intervention. The intervention is comprised of a patient navigator, text message questionnaire, and informational video.",[338,339,26],"Gastrointestinal Cancer","Hematologic Cancer",[338,339,26],"2025-11-04",{"date":343,"type":35},"2025-11-05",{"date":345,"type":35},"2023-04-03",{"date":347,"type":21},"2028-07-30",{"name":349,"class":42},"Nadine McCleary, MD, MPH",3,{"id":352,"slug":353,"hasResults":11,"nctId":354,"briefTitle":355,"officialTitle":356,"acronym":357,"eligibilityCriteria":358,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":359,"targetDuration":4,"studyType":53,"phases":361,"briefSummary":362,"conditions":363,"keywords":368,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":376,"lastUpdatePostDateStruct":377,"startDateStruct":379,"completionDateStruct":381,"leadSponsor":383,"locationsCount":384},"100443348","a-study-evaluating-the-integrative-medicine-at-home-imhome-program-in-people-with-cancer-100443348","NCT05053230","A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer","Integrative Medicine for Patient-reported Outcomes, Values, and Experience (IMPROVE)","IMPROVE","Inclusion Criteria:\n\n* Age ≥ 18 years or older\n* Karnofsky score 60 or greater\n* Life expectancy greater than six months\n* English speaking\n\nAdditional Inclusion Criteria for Head and Neck, Thoracic, Gynecologic, Melanoma and Breast Baskets\n\n* Patients with a diagnosis of head and neck tumors, thoracic tumors, gynecological tumors, melanoma, breast cancer, or gynecologic cancer\n* Actively receiving systemic oncological treatment or radiotherapy, or within 4 weeks of radiotherapy completion or primary cytoreductive surgery\n* Worst fatigue over the last 7 days rated 4 or greater on (0-10 scale)\n\nAdditional Inclusion Criteria for First Remission Gynecologic Cancer Basket\n\n* Patients with a diagnosis or clinical suspicion of gynecologic malignancy who have completed definitive first line treatment (maintenance hormonal or targeted therapies are allowed)\n\nAdditional Inclusion Criteria for the Advanced Cancer Basket:\n\n* Patients with a diagnosis of Stage III or IV lung cancer; any stage pancreatic cancer, unresectable cholangiocarcinoma, unresectable liver cancer, unresectable ampullary or peri-ampullary cancer, or other stage IV gastrointestinal cancer; stage III or IV ovarian or fallopian tube cancers or other stage IV gynecologic cancer; stage IV breast cancer; stage III testicular cancer or any stage IV genitourinary cancer; stage IV sarcoma; stage IV melanoma; stage IV endocrine cancer; lymphoma, myeloma, or Leukemia\n* Actively receiving oncological treatment, radiotherapy or active surveillance\n\nAdditional Inclusion Criteria for the Cancer Survivor Basket:\n\n* Completed active cancer treatment (e.g., surgery, radiation, chemotherapy) (maintenance hormonal or targeted therapies are allowed).\n* Worst fatigue over the last 7 days rated 4 or greater on (0-10 scale)\n\nExclusion Criteria:\n\n* Cognitive impairment that would preclude response to study assessments or require the use of Legally Authorized Representatives\n* Unwilling to accept random assignment\n* Concurrently enroll onto ongoing competing trials of integrative medicine interventions with symptom\u002Ftoxicity as primary outcome. Note, however, patient will be allowed to enroll on other therapeutic protocols",{"count":360,"type":21},480,[196],"The overarching long-term goal of the Integrative Medicine for Patient-reported Outcomes Values and Experience (IMPROVE) research program is to evaluate whether integrating a virtual mind-body programming, Integrative Medicine at Home (IM@Home), will improve patient perceived values, outcomes, and experiences as they undergo systemic cancer treatment such as chemotherapy, immunotherapy, radiotherapy, targeted agents, cytoreductive surgery.",[61,364,365,26,201,366,153,367],"Head and Neck Tumor","Thoracic Tumor","Gynecologic Tumor","Ovarian Cancer",[61,369,370,371,372,373,374,375],"head and neck tumor","thoracic tumors","gynecological tumors","melanoma","21-369","Memorial Sloan Kettering Cancer Center","ovarian cancer","2025-10-08",{"date":378,"type":35},"2025-10-09",{"date":380,"type":35},"2021-09-20",{"date":382,"type":21},"2026-09-20",{"name":374,"class":42},7,{"id":386,"slug":387,"hasResults":11,"nctId":388,"briefTitle":389,"officialTitle":390,"acronym":4,"eligibilityCriteria":391,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":392,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":394,"conditions":395,"keywords":396,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":398,"lastUpdatePostDateStruct":399,"startDateStruct":401,"completionDateStruct":403,"leadSponsor":405,"locationsCount":79},"100564749","fatigue-and-molecular-mechanisms-in-cancer-patients-receiving-ccrt-100564749","NCT06633224","Fatigue and Molecular Mechanisms in Cancer Patients Receiving CCRT","An Evaluation of Changes in the Relationships Between Fatigue and Molecular Mechanisms in Cancer Patients Receiving Curative-Intent Combined Chemotherapy and Radiation Therapy (CCRT)","Inclusion Criteria:\n\n* Participants have not received any prior treatment (i.e., cancer systemic therapies or radiation therapy) in the month except surgery or inductive Chemotherapy (CTX).\n* Participants receiving \\>= 15 fractions.\n* Participants is male or female and is \\>18 years of age on the day of signing the informed consent.\n* Ability to understand a written informed consent document.\n* Able and willing to complete all of the study questionnaires and provide blood and stool samples prior to, midway, and following the completion of treatment.\n* Willing to have medical records reviewed for clinical information.\n* Able to read, write and understand English or Spanish.\n\nExclusion Criteria:\n\n* Contraindication to phlebotomy for removal of approximately 50 mL of peripheral blood within 6 week period (Institutional Review Board (IRB) limit).",{"count":393,"type":21},125,"Cancer-related fatigue (CRF) is a significant problem for cancer patients. This prospective, basic science, observational study will evaluate for changes in CRF associated with molecular characteristics prior to, during, and at the completion of non-investigational, standard-of-care, combined chemotherapy and radiation therapy (CCRT) and to develop and assess predictive models for CRF severity.",[65,26,201,61,338],[397],"Basic Science Research","2025-09-09",{"date":400,"type":35},"2025-09-16",{"date":402,"type":35},"2024-12-27",{"date":404,"type":21},"2027-09-01",{"name":406,"class":42},"University of California, San Francisco",{"id":408,"slug":409,"hasResults":11,"nctId":410,"briefTitle":411,"officialTitle":412,"acronym":4,"eligibilityCriteria":413,"healthyVolunteers":11,"sex":17,"minAge":414,"maxAge":4,"enrollmentInfo":415,"targetDuration":4,"studyType":53,"phases":417,"briefSummary":418,"conditions":419,"keywords":4,"overallStatus":157,"whyStopped":4,"lastUpdateSubmitDate":424,"lastUpdatePostDateStruct":425,"startDateStruct":427,"completionDateStruct":429,"leadSponsor":431,"locationsCount":4},"100564863","scintix-bgrt-using-rmrs-in-solid-and-soft-tissue-tumors-100564863","NCT06634706","SCINTIX [BgRT} Using RMRS in Solid and Soft Tissue Tumors","Performance and Safety of Biology-Guided Radiotherapy Using the RefleXion Medical Radiotherapy System in in a Variety of Solid and Soft Tissue Tumors (BIOGUIDE-X2)","Inclusion Criteria:\n\n1. Age greater than 21 years.\n2. A new or prior diagnosis of biopsy-proven cancer.\n3. At least one active non-osseous primary or metastatic tumor that is located in one of the assigned anatomical groupings and dispositioned to undergo 3-5 fractions of SBRT. A lesion is considered active if viable malignancy is confirmed either by biopsy or by diagnostic imaging (as interpreted by the multidisciplinary care team).\n4. Target tumor size ≥2cm and ≤5cm.\n5. Target tumor is discrete and assessed by investigator to meet diagnostic PET screening criteria for BgRT candidacy:\n\n   1. SUVmax≥6, as assessed on diagnostic PET\u002FCT performed within 60 days of enrollment with no new intervening oncologic therapies.\n   2. Ratio of target tumor SUVmax to SUVmean of local background region (defined as a 3 mm shell 1.5 cm from the target tumor) is greater than 6, as assessed on diagnostic PET\u002FCT performed within 60 days of enrollment with no new intervening oncologic therapies.\n6. ECOG Performance Status 0-3.\n7. Must have completed any other oncologic therapies at least 15 days prior to planned start of study procedures (preferably 30 days) and must have no plans to initiate systemic therapy until after study follow up is complete -OR- must be recorded by physician to have an active lesion that is unresponsive to ongoing systemic therapy.\n8. Females of childbearing potential should have a negative urine or serum pregnancy test within 14 days prior to initiation of study scans.\n\nExclusion Criteria:\n\n1. Clinically significant blood glucose abnormalities that preclude a satisfactory FDG PET\u002FCT scan.\n2. Lung parenchymal and bone target tumors\n3. At the physician's discretion regarding expected target motion, FDG-avid structures not intended for radiation are within:\n\n   1. 3 cm from target on diagnostic PET\u002FCT in directions where limited target motion is expected\n   2. 4 cm from target on diagnostic PET\u002FCT in directions where sizable target motion is expected\n4. Known allergy to FDG.\n5. Known psychiatric or substance abuse disorder that would interfere with conduct of the study.\n6. Pregnant, breast-feeding or expecting to conceive during the study.\n7. Patient weight exceeding the weight limit outlined per user manual.\n8. Patients with pacemakers and other implantable devices deemed at high risk by the treating physician for complications secondary to radiotherapy, according to institutional guidelines and published guidelines (e.g. AAPM task group-203).\n9. Active inflammatory bowel disease, scleroderma, or other disorder deemed by the treating physician to put the patient at risk for excess toxicity in the setting of external beam radiation therapy (EBRT) or FDG injection.","21 Years",{"count":416,"type":21},96,[196],"This study proposes 6 anatomic groupings which each can be defined similarly as the \"head and neck\" grouping above. These 6 groupings are: (1) Head and Neck, (2) Thoracic not including lung parenchymal, (3) Hepatobiliary and other non-hepatobiliary abdominal tumors, (4) Retroperitoneal, (5) Pelvic, and (6) Distributed or orphan. The study is designed to gather essential imaging data on the RefleXion Medical Radiotherapy System (RMRS) to validate the accuracy of FDG-directed BgRT, also known as SCINTIX therapy, in various anatomical groupings. Study subjects will go through the entire SCINTIX treatment workflow, including radiopharmaceutical administration and live PET imaging, but without turning on the treatment beam. Collected data will be used offline to generate the set of machine instructions that would have been used during treatment delivery to calculate the \"emulated\" BgRT dose distribution, i.e., what the delivered dose would have been had the treatment beam been turned on during the session. The 6th category (\"Distributed or orphan\") is meant to capture tumor types that can manifest across anatomies and\u002For for which utilization of stereotactic radiotherapy for treatment is relatively rare, with lymphomas being a prototypical example.",[26,61,420,421,422,423],"Pelvic Cancer","Hepatobiliary Carcinoma in Situ","Retroperitoneal Cancer","Distributed and Orphan Tumors","2025-08-12",{"date":426,"type":35},"2025-08-13",{"date":428,"type":21},"2025-12-01",{"date":430,"type":21},"2027-01-01",{"name":432,"class":115},"RefleXion Medical",{"id":434,"slug":435,"hasResults":11,"nctId":436,"briefTitle":437,"officialTitle":438,"acronym":4,"eligibilityCriteria":439,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":440,"enrollmentInfo":441,"targetDuration":4,"studyType":53,"phases":443,"briefSummary":444,"conditions":445,"keywords":446,"overallStatus":157,"whyStopped":4,"lastUpdateSubmitDate":448,"lastUpdatePostDateStruct":449,"startDateStruct":451,"completionDateStruct":453,"leadSponsor":455,"locationsCount":79},"100560742","validate-the-safety-and-feasibility-of-the-ct-guided-interventional-robot-in-percutaneous-lung-cryablation-procedures-100560742","NCT06581107","Validate the Safety and Feasibility of the CT-guided Interventional Robot in Percutaneous Lung Cryablation Procedures","Validate the Feasibility and Safety of the Robot System by Investgating the CT-fluoroscopy Guidance in Percutaneous Lung Cryablation Procedures of Participants With Lung Cancer","Inclusion Criteria:\n\n1. Participants suffering from lung cancer and judged by the investigator to be indicated for cryoablation procedures;\n2. Participants voluntarily participate in this clinical study and sign the informed consent form;\n3. Participants cannot undergo surgical treatment due to contraindications to surgical resection of lung cancer;\n4. Participants can understand the study and cooperate with the study procedures, and are able to carry out follow-up observation as required.\n\nExclusion Criteria:\n\n1. Participants have diffuse lesions in both lungs that cannot be improved by ablative therapy;\n2. Participants suffer from extensive pleural metastases with massive pleural effusion;\n3. Participants have tumors adjacent to the mediastinal blood vessels, contrast allergy, or inability to cooperate, which makes it difficult to choose the route of needle insertion;\n4. Participants with lesions encircling blood vessels where ablation may lead to severe bleeding;\n5. Participants with severely impaired lung function, with maximal ventilation \\\u003C40%;\n6. Participants with a low platelet count and severe coagulation abnormalities who cannot tolerate the procedure (anticoagulant therapy and\u002For anticoagulant medication should be discontinued for more than 1 week prior to ablation therapy);\n7. Participants with poor general condition (multiple metastases throughout the body, severe infections, high fever), obvious malignant disease, severe insufficiency of vital organ function, severe anemia, and disorders of nutritional metabolism that cannot be improved in the short term;\n8. Allergy to contrast media or anesthetics;\n9. Pregnant or breastfeeding women, or those who plan to have children during the clinical study;\n10. Participants with known addiction to drugs, alcohol, etc.;\n11. Participants with psychiatric disorders who have no self-control and are unable to communicate clearly;\n12. Participants who have participated in other drug, biologic, or medical device clinical studies without meeting the primary study endpoint timeframe prior to enrollment in this study;\n13. Any other conditions that the investigator deems unsuitable for participation in this clinical study.","75 Years",{"count":442,"type":21},20,[196],"This study aims to investigate whether the interventional robot can be well and safely used for percutaneous lung cryoablation in patients with lung cancer. The robot allows radiologists to remotely control the needle insertion process under CT fluoroscopy guidance.\n\nThe main questions this study aims to answer are:\n\n1. Whether the robot-assisted Cryoablation method can achieve complete the coverage of preoperatively planned ablation areas;\n2. Whether the robot-assisted Cryoablation method can improve the success rate for radiologists to insert the needle into the target lesion area without additional needle adjustment;\n3. Whether the robot-assisted Cryoablation method can reduce puncture time, ablation time and procedure time;\n4. Whether the robot-assisted Cryoablation method can decrease the patient's complication occurrence rate;\n5. Whether the robot-assisted Cryoablation method can obtain decent Evaluation of system performance.",[25,26],[447],"Image-guided Biopsy; Robot-assisted procedures","2024-08-29",{"date":450,"type":35},"2024-09-03",{"date":452,"type":21},"2024-09-15",{"date":454,"type":21},"2025-02-28",{"name":456,"class":42},"Tianjin Medical University Cancer Institute and Hospital",{"id":458,"slug":459,"hasResults":11,"nctId":460,"briefTitle":461,"officialTitle":462,"acronym":463,"eligibilityCriteria":464,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":465,"targetDuration":4,"studyType":53,"phases":467,"briefSummary":468,"conditions":469,"keywords":471,"overallStatus":157,"whyStopped":4,"lastUpdateSubmitDate":475,"lastUpdatePostDateStruct":476,"startDateStruct":478,"completionDateStruct":480,"leadSponsor":482,"locationsCount":4},"100558980","phase-1-reirradiation-dose-escalation-in-thoracic-cancers-100558980","NCT06558175","Reirradiation Dose Escalation in Thoracic Cancers","A Safety and Efficacy Trial of Reirradiation Dose Escalation in Thoracic Cancers: Re-evaluating Previous Dose and Allowing Increasing Recovery (REPAIR)","REPAIR","Inclusion Criteria:\n\n* Pathologically (histologically or cytologically) proven diagnosis of malignancy, with disease in the thorax requiring re-irradiation for any treatment intent. This may include primary lung cancer of any type, esophageal cancer, recurrences, and\u002For metastasis from any primary. The intrathoracic disease at the time of enrollment does not itself require a biopsy if a prior biopsy has been obtained at that location or another body site. If the risk of biopsy is unacceptable and there is no prior confirmation of malignancy even at the time of the initial course of radiation, enrollment is permitted provided that the case is discussed at a multidisciplinary tumor board or peer-review rounds.\n* Must have received prior photon thoracic radiotherapy ≥ 6 months ago\n* Life expectancy \\> 6 months.\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-2\n* Age ≥ 18 years\n* The current radiation course, when added to the previous radiation doses, exceeds the normal tissue constraints used for de novo treatments for esophagus, heart, lungs, trachea, bronchus, great vessels, or brachial plexus. Forgiveness of the previous dose (i.e. reduction of the previous dose in the cumulative dose calculation) is required to meet constraints. Submission of a pre-plan summary showing the estimated accumulation of current and previously delivered doses is required for registration.\n\nExclusion Criteria:\n\n* Persistent toxicity from previously delivered radiation therapy\n* Prior development of symptomatic radiation pneumonitis or immunotherapy-related pneumonitis from previous treatment, even if resolved\n* Cumulative radiation dose for all organs-at-risk is already below dose constraints without a recovery factor applied, or with a recovery factor less than the current dose level of the trial. This will be confirmed by the enrolling team after the planning is completed.\n* The reirradiation dose-limiting structure is expected to be spinal cord, chest wall, and\u002For stomach.\n* Any prior thoracic radiotherapy \\\u003C 6 months ago; OR prior thoracic radiotherapy delivered twice daily (compensation for holiday breaks are OK), thoracic radiotherapy delivered by brachytherapy, radionuclides, proton beams, or electron beams.\n* Plans for patient to receive daily adaptive radiotherapy in current plan (computed tomography or magnetic resonance based).\n* Plans for the patient to receive other local therapy (including standard fractionated radiotherapy and\u002For surgery) while on this study, except at disease progression.\n* Concurrent systemic therapy (i.e. on the same days as radiation) is not allowed, EXCEPT for patients being treated for intrathoracic lung cancer (NSCLC or SCLC) with curative intent.\n* For other patients receiving systemic therapy, they are still eligible for enrollment as long as there is a break in systemic therapy during the course of radiation. For example, if a patient has been on palliative pemetrexed and is planning to continue, they can still be enrolled and would continue to receive pemetrexed; reirradiation would be delivered between cycles, possibly requiring a break in systemic therapy. See Section 6.9 for further details.\n* Prior surgical intervention that has significantly changed the position of an organ-at-risk that is expected to be a dose-limiting structure.\n* Pregnancy\n* The following autoimmune and connective tissue diseases will be excluded: Scleroderma and Systemic lupus erythematosus.\n* Patients with interstitial lung disease (ILD).",{"count":466,"type":21},48,[55],"This is a study involving patients with recurrence, metastasis, or new primary malignancies in the thorax requiring radiation and who have previously received radiotherapy to the thorax, where re-irradiation is expected to exceed the dose constraints used for de novo treatments.\n\nCurrently, when this group of patients needs another set of radiotherapy, there is a dose limitation based on a percentage of the previous treatment's dose. However, this dose often limits the effectiveness of repeated treatment, with little scientific support for such. Therefore, this study aims to determine the maximally tolerated dose of reirradiation in the thorax, with dose escalation implemented by sequentially increasing the normal tissue recovery factors (i.e. repair factors) to the previously delivered dose.\n\nUsing a recovery factor equation associated with a 35% or lower rate of grade 3-5 treatment-related toxicity occurring within 1 year of treatment, accrual will start at level 1 (recovery factor = 10% at 6 months + 0.75% per month thereafter). Patients will be assigned to recovery factors using the TITE-CRM model. The model will use all available information from previously accrued patients to assign the highest dose with a predicted risk of grade 3-5 toxicity of 35% or less.",[26,25,470],"Esophageal Cancer",[472,473,474,287],"Re-irradiation","Toxicity","Dose escalation","2024-08-14",{"date":477,"type":35},"2024-08-16",{"date":479,"type":21},"2024-10-30",{"date":481,"type":21},"2027-01-29",{"name":483,"class":42},"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's",{"id":485,"slug":486,"hasResults":11,"nctId":487,"briefTitle":488,"officialTitle":488,"acronym":4,"eligibilityCriteria":489,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":221,"enrollmentInfo":490,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":492,"conditions":493,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":496,"lastUpdatePostDateStruct":497,"startDateStruct":499,"completionDateStruct":501,"leadSponsor":503,"locationsCount":79},"100466117","safety-and-efficacy-of-sbrt-in-the-treatment-of-thoracic-malignant-tumors-at-different-sites-100466117","NCT05349552","Safety and Efficacy of SBRT in the Treatment of Thoracic Malignant Tumors at Different Sites","Inclusion Criteria:\n\n* Pathological diagnosis was malignant tumor.\n* The location of the target lesion belongs to one of five types and the lesion diameter is ≤ 5cm.\n* There is no extensive systemic metastasis or although there is metastasis, the metastasis have been controlled by previous treatment.\n* KPS\\>70, no serious or uncontrolled underlying diseases, such as severe or uncontrolled hypertension, diabetes, cardiovascular and cerebrovascular diseases and organ dysfunction, and patients are expected to be tolerated by radiotherapy.\n\nExclusion Criteria:\n\n* Poor basic pulmonary function or symptom correlation caused by various reasons, unable to lie flat or cooperate with treatment.\n* The general condition is poor, and the expected survival time is less than 3 months.\n* Psychiatric patients or poor compliance, unable to cooperate to complete treatment.\n* For other reasons, the researcher believes that it is not suitable to participate in this trial.",{"count":491,"type":21},120,"SBRT (stereotactic radiotherapy) can provide a higher dose to the target area without increasing the risk of surrounding normal tissue \u002F organ injury in selective cases. At present, SBRT has been widely used in radiotherapy of lung cancer and it can also play a better local control for lung metastasis.\n\nHowever, there are parallel organs and series organs in the chest, and different organs have different tolerance to radiotherapy, so the toxicities of SBRT in different sites are different, and the prescription dose is also different.\n\nThis study intends to make a detailed division of the chest region and explore the safety and efficacy of SBRT in different areas. It is divided into four types: chest wall type: the lesion is directly adjacent or overlapped with the chest wall; peripheral type: the lesion is more than 1cm away from the chest wall and more than 2cm away from the bronchial tree; central type: the lesion is less than 2cm away from the bronchial tree; ultral-central type: the lesion is directly adjacent or overlapped with the mediastinal structure.\n\n48-60Gy \u002F 4-10f (EQD2 = 62.5Gy \\~ 99.7Gy) was given according to the location of the tumor. Main outcome measures are local progression free survival and radiation toxicities; secondary outcome measure is overall survival.",[494,26,495],"Radiotherapy","Safety and Efficacy","2023-12-22",{"date":498,"type":35},"2023-12-27",{"date":500,"type":35},"2022-05-01",{"date":502,"type":21},"2027-04-30",{"name":504,"class":42},"Peking University Third Hospital"]